Frontier IP Group plc Director Declaration (0695C)

TIDMFIPP

RNS Number : 0695C

Frontier IP Group plc

26 September 2018

26 September 2018

Frontier IP Group plc

("Frontier IP" or the "Group")

Director Declaration

Frontier IP, which specialises in commercialising university intellectual property, makes the following updated disclosures in respect of Neil Crabb, CEO of Frontier IP, pursuant to Schedule 2(g) of the AIM Rules for Companies:

a) Mr Crabb was appointed as a director of B1 Medical Limited on 14 July 2006 and was a director when the company entered into compulsory liquidation on 1 November 2012. B1 Medical Limited was dissolved on 5 February 2013.

b) Mr Crabb was appointed as a director of Intelligent Flow Solutions Limited on 27 March 2012 and was a director when the company entered into compulsory liquidation on 26 October 2016.

There are no further disclosures required pursuant to Schedule 2(g).

Enquiries:

 
 Frontier IP Group plc                         T: 0131 240 1251 
 Neil Crabb, Chief Executive 
 Andrew Johnson, Communications & Investor     M: 07464 546 
  Relations                                     025 
 www.frontierip.co.uk 
 
 Cenkos Securities plc (Nominated Adviser      T: 0131 220 6939 
  and Joint Broker) 
 Neil McDonald / Beth McKiernan 
 
 Peterhouse Corporate Finance Limited (Joint 
  Broker)                                      T: 020 7469 0935 
 Lucy Williams 
 
 Kreab (Financial PR)                          T: 0207 074 1800 
 Robert Speed / Matthew Jervois 
 

Notes to Editors:

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RDNMMGZLVVGGRZM

(END) Dow Jones Newswires

September 26, 2018 12:12 ET (16:12 GMT)